Sep 8, 2025 07:01AM Biodexa enrolls first patients in Phase 3 trial for FAP treatment

Aug 5, 2025 06:38AM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 6c

Jul 28, 2025 07:00AM Biodexa initiates phase 3 trial for FAP treatment eRapa

Jul 8, 2025 08:03AM Recursion (RXRX) acquires full rights to oral HPP treatment REV102

Jul 3, 2025 04:19AM Morgan Stanley Assumes Recursion Pharmaceuticals (RXRX) at Equalweight

Jun 16, 2025 07:35AM Recursion Pharmaceuticals (RXRX) PT Lowered to $5 at Morgan Stanley

Jun 10, 2025 06:21AM Recursion Pharmaceuticals (RXRX) to cut 20% staff

Jun 6, 2025 10:01AM Recursion (RXRX) and MIT researchers unveils Boltz-2 biomolecular model

May 6, 2025 03:18PM Recursion Pharmaceuticals (RXRX) call put ratio 3.1 calls to 1 put as share price down 11.2%

May 6, 2025 05:40AM Recursion Pharmaceuticals (RXRX) PT Lowered to $8 at BofA Securities

May 5, 2025 06:31AM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q1 EPS by 1c

Apr 16, 2025 08:42AM Recursion Pharmaceuticals (RXRX) and HealthVerity partner to enhance trial analysis

Apr 8, 2025 08:04AM Recursion Pharmaceuticals (RXRX) Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Mar 18, 2025 08:03AM Recursion Pharmaceuticals (RXRX) Appoints Namandjé Bumpus and Elaine Sun to its Board

Feb 28, 2025 02:06PM TD Cowen Reiterates Hold Rating on Recursion Pharmaceuticals (RXRX)

Feb 28, 2025 06:36AM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q4 EPS by 12c

Feb 18, 2025 11:10AM Recursion's Altitude Lab startup has raised $154 million

Feb 5, 2025 05:27PM Recursion Pharmaceuticals (RXRX) reports date from phase 2 of REC-994 studies

Jan 7, 2025 09:15AM Recursion Pharmaceuticals (RXRX) Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials

Dec 20, 2024 05:00AM Key takeaways from the 2024 BofA AI Conference

Nov 20, 2024 03:13PM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX)

Nov 13, 2024 09:09AM Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) Shareholders Approve the Proposed Merger

Nov 12, 2024 04:55PM Recursion Pharmaceuticals (RXRX) Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Nov 7, 2024 04:32PM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 1c

Oct 22, 2024 08:03AM Recursion Pharmaceuticals (RXRX) announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides diffi

Oct 2, 2024 02:17PM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )

Oct 2, 2024 08:02AM Recursion Pharmaceuticals (RXRX) Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphom

Sep 4, 2024 07:12AM Recursion Pharmaceuticals (RXRX) PT Lowered to $11 at Needham

Sep 3, 2024 03:00PM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )

Sep 3, 2024 02:54PM TD Cowen Reiterates Hold Rating on Recursion Pharmaceuticals (RXRX )

Sep 3, 2024 11:50AM Recursion Pharmaceuticals (RXRX) PT Lowered to $6 at Jefferies

Sep 3, 2024 08:19AM Recursion Pharmaceuticals (RXRX) Declines 7% Following Phase 2 Data of REC-994

Sep 3, 2024 08:00AM Recursion (RXRX) Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for CCM, has Met its Primary Endpoint of Safety and Tolerability

Aug 8, 2024 07:41AM Recursion Pharmaceuticals (RXRX) to Merge with Exscientia (EXAI)

Aug 8, 2024 07:37AM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c

Jul 9, 2024 05:17AM Jefferies Starts Recursion Pharmaceuticals (RXRX ) at Hold

Jun 27, 2024 05:45AM Recursion Pharmaceuticals (RXRX) Prices 30.77M Share Offering at $6.50/sh

Jun 26, 2024 04:56PM After-hours movers: Micron Technology, Levi, AeroVironment, and more

Jun 26, 2024 04:07PM Recursion Pharmaceuticals (RXRX) Announces Proposed $200M Share Offering

Jun 26, 2024 08:59AM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )